Czech National Bank Acquires 5,974 Shares of Zoetis Inc. $ZTS

Key Points

• The Czech National Bank increased its ownership of Zoetis Inc. by 5.8% in Q2, acquiring an additional 5,974 shares, bringing its total to 108,824 shares valued at $16.97 million.
• Zoetis reported $1.76 earnings per share for the last quarter, surpassing estimates and showing a revenue increase of 4.2% year-over-year.
• Analysts maintain a Moderate Buy rating for Zoetis, with an average price target of $200.88, despite mixed ratings from several firms.

Czech National Bank lifted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 108,824 shares of the company's stock after acquiring an additional 5,974 shares during the period. Czech National Bank's holdings in Zoetis were worth $16,971,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB lifted its position in Zoetis by 3.6% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 40,201 shares of the company's stock worth $6,269,000 after purchasing an additional 1,397 shares during the period. IAM Advisory LLC lifted its holdings in shares of Zoetis by 2.6% in the second quarter. IAM Advisory LLC now owns 10,362 shares of the company's stock valued at $1,616,000 after buying an additional 260 shares during the period. Everpar Advisors LLC lifted its holdings in shares of Zoetis by 11.6% in the second quarter. Everpar Advisors LLC now owns 1,677 shares of the company's stock valued at $262,000 after buying an additional 174 shares during the period. Webster Bank N. A. lifted its holdings in shares of Zoetis by 25.3% in the second quarter. Webster Bank N. A. now owns 554 shares of the company's stock valued at $86,000 after buying an additional 112 shares during the period. Finally, NBC Securities Inc. lifted its holdings in Zoetis by 2.1% in the 2nd quarter. NBC Securities Inc. now owns 13,179 shares of the company's stock valued at $2,055,000 after acquiring an additional 271 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Up 0.2%

Zoetis stock traded up $0.23 during mid-day trading on Thursday, hitting $147.16. The company's stock had a trading volume of 2,739,409 shares, compared to its average volume of 2,257,212. The firm's 50 day moving average is $151.43 and its 200 day moving average is $156.76. The company has a market cap of $65.22 billion, a PE ratio of 25.33, a price-to-earnings-growth ratio of 2.36 and a beta of 0.89. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ZTS shares. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reiterated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.